Department of Hepatobiliary Surgery, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi, 710032, People's Republic of China.
Department of Clinical Oncology, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi, 710032, People's Republic of China.
Cancer Lett. 2017 Jul 1;397:33-42. doi: 10.1016/j.canlet.2017.03.004. Epub 2017 Mar 10.
Cancer-associated fibroblasts (CAFs) play a pivotal role in regulating tumour progression. Therefore, understanding how CAFs communicate with hepatocellular carcinoma (HCC) is crucial for HCC therapy. Recently, exosomes have been considered an important "messenger" between cells. In this study, we performed microRNA (miRNA) sequencing of exosomes derived from CAFs and corresponding para-cancer fibroblasts (PAFs) of HCC patients. We found a significant reduction in the miR-320a level in CAF-derived exosomes. Using exogenous miRNAs, we demonstrated that stromal cells could transfer miRNA to HCC cells. In vitro and in vivo studies further revealed that miR-320a could function as an antitumour miRNA by binding to its direct downstream target PBX3 to suppress HCC cell proliferation, migration and metastasis. The miR-320a-PBX3 pathway inhibited tumour progression by suppressing the activation of the MAPK pathway, which could induce the epithelial-mesenchymal transition and upregulate cyclin-dependent kinase 2 (CDK2) and MMP2 expression to promote cell proliferation and metastasis. In xenograft experiments involving CAFs mixed with MHCC97-H cells, miR-320a overexpression in CAFs could inhibit tumourigenesis. Therefore, these data suggest that CAF-mediated HCC tumour progression is partially related to the loss of antitumour miR-320a in the exosomes of CAFs and that promoting the transfer of stromal cell-derived miR-320a might be a potential treatment option to overcome HCC progression.
癌症相关成纤维细胞(CAFs)在调节肿瘤进展中发挥着关键作用。因此,了解 CAFs 如何与肝细胞癌(HCC)相互作用对于 HCC 的治疗至关重要。最近,外泌体被认为是细胞间重要的“信使”。在本研究中,我们对来自 HCC 患者的 CAF 和相应的癌旁成纤维细胞(PAF)的外泌体进行了 microRNA(miRNA)测序。我们发现 CAF 来源的外泌体中的 miR-320a 水平显著降低。通过外源性 miRNAs,我们证明了基质细胞可以将 miRNA 转移到 HCC 细胞中。体内和体外研究进一步表明,miR-320a 可以通过与其直接下游靶基因 PBX3 结合来抑制 HCC 细胞的增殖、迁移和转移,作为一种抗肿瘤 miRNA 发挥作用。miR-320a-PBX3 通路通过抑制 MAPK 通路的激活来抑制肿瘤进展,MAPK 通路可诱导上皮-间充质转化,并上调细胞周期蛋白依赖性激酶 2(CDK2)和 MMP2 的表达,从而促进细胞增殖和转移。在涉及 CAFs 与 MHCC97-H 细胞混合的异种移植实验中,CAFs 中 miR-320a 的过表达可抑制肿瘤发生。因此,这些数据表明,CAF 介导的 HCC 肿瘤进展部分与 CAF 外泌体中抗肿瘤 miR-320a 的丢失有关,促进基质细胞衍生的 miR-320a 的转移可能是克服 HCC 进展的一种潜在治疗选择。